Optimizing transcriptome-based synthetic lethality predictions to improve precision oncology in early-stage breast cancer: BC-SELECT

Yewon Kim,Matthew Nagy,Becca Pollard,Padma Sheila Rajagopal

DOI: https://doi.org/10.1101/2024.08.15.608073

2024-08-21

Abstract:Introduction: Patients with early-stage breast cancer currently do not have approaches to predict relative benefit from targeted therapies or immunotherapies (as with Oncotype in hormone-receptor positive (HR+) patients for chemotherapy). SELECT, a computational tool that leverages genetic interactions, such as synthetic lethality or rescue (SL or SR), using transcriptomic data to predict treatment response. SELECT and its commercial adaptation, ENLIGHT, predict patient survival response to therapy in retrospective data across cancer types. However, the breast cancer-specific therapies tested by those algorithms are largely limited to endocrine therapies or HER2-directed therapies. This does not address current treatment options, such as PARP inhibitors or immunotherapy, that may compete without clear guidance for patients. We sought to improve the application of transcriptome-based genetic interactions in patients with early-stage breast cancer by adapting the SELECT framework specifically for this population. This adaptation, BC-SELECT, seeks to optimize predictive accuracy and therapeutic guidance for patients with breast cancer. Methods: SELECT involves two main steps: (1) a training step that, for a given drug target, constructs a library of clinically relevant candidate SL/SR partner genes, and (2) a testing/validation step that calculates patients' predicted response scores in unseen studies based on the relative expression of the candidate partner genes. We adapt this approach in BC-SELECT by using breast cancer-specific expression data and breast cancer trials in the training step, then performing testing/validation on breast cancer clinical trials. We evaluate the prediction accuracy of BC-SELECT using multiple statistical tests. Results: BC-SELECT predicted treatment response in 11 clinical trials in breast cancer (not used for training), with 5 out of 8 targeted therapy trials (including PARP inhibitors) showing ROC-AUCs > 0.6, and all 3 immunotherapy trials showing ROC-AUCs > 0.7. BC-SELECT showed empirical statistical significance and surpassed our 2.5% cutoff threshold compared to chance in 7/11 datasets. The algorithm outperformed the original SELECT and ENLIGHT for immunotherapy prediction in breast cancer. Conclusion: In the early-stage setting, where pre-treatment predictors of response are limited for triple-negative and HER2-positive disease, BC-SELECT predicts patient responses better than chance and better than pre-existing algorithms for targeted therapies and immunotherapies. These findings underscore the algorithm's potential as a decision support tool for refining precision medicine, particularly prioritization of clinical treatments, for patients with early-stage breast cancer.

Bioinformatics